Candel Therapeutics, Inc. (CADL) 8-K Current Report: February 23, 2026
Filed: February 23, 2026
Health Care
Biological Products, (No Diagnostic Substances)Candel Therapeutics, Inc. (CADL) 8-K current report filed with SEC EDGAR on February 23, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 1.01: Entry into a Material Definitive Agreement
- Item 8.01: Other Events
Candel Therapeutics, Inc. 8-K Feb 23, 2026 Event Analysis
Item 1.01 · Entry into a Material Definitive Agreement
- • Offering priced at $5.45/share for 18,348,624 firm shares; underwriters hold 30-day option for 2,752,293 additional shares
- • Net proceeds ~$93.5M (or ~$107.6M if overallotment exercised fully) — meaningful cash infusion for a clinical-stage biotech
- • Proceeds earmarked for CAN-2409 prostate cancer commercial launch readiness and Phase 3 NSCLC trial costs
- • Underwriters: Citigroup, Cantor Fitzgerald, and Stifel — institutional-grade syndicate signals credible market support
- • Closing expected ~Feb 23, 2026; significant dilution event for existing shareholders given share count increase
Item 8.01 · Other Events
- • Offering raises ~$93.5M net proceeds, extending cash runway into Q1 2028
- • Underwriters hold option to purchase additional shares, potentially increasing total raise above $93.5M
- • Runway extension is material: funds operational burn and capex for ~2 years from offering date
- • Standard forward-looking caveat noted — actual burn rate could shorten the Q1 2028 timeline
Other Candel Therapeutics, Inc. 8-K Filings
Get deeper insights on Candel Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.